TY - JOUR
T1 - Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy
T2 - A sub-study from the NeoALTTO phase III trial
AU - Azim, Hatem A.
AU - Rothé, Francoise
AU - Aura, Claudia Monica
AU - Bavington, Malcolm
AU - Maetens, Marion
AU - Rouas, Ghizlaine
AU - Gebhart, Geraldine
AU - Gamez, Cristina
AU - Eidtmann, Holger
AU - Baselga, José
AU - Piccart-Gebhart, Martine
AU - Ellis, Catherine
AU - Vuylsteke, Peter
AU - Cure, Hervé
AU - Domont, Julien
AU - Ferro, Antonella
AU - Toral-Peña, Juan Carlos
AU - de Azambuja, Evandro
AU - Sotiriou, Christos
AU - Di Cosimo, Serena
AU - Ignatiadis, Michail
PY - 2013/12
Y1 - 2013/12
N2 - Background: The role of circulating tumor cells (CTCs) in HER2-positive breast cancer patients receiving neoadjuvant therapy is unclear. Patients & methods: We describe the CTC detection rate, HER2 phenotyping and pathological complete response (pCR) in patients enrolled in the NeoALTTO phase III trial. Participation in the CTC sub-study was optional. CTC evaluation was performed centrally using CellSearch® at baseline, week 2 and week 18 (prior to surgery) of neoadjuvant therapy. Results: Samples for CTC analysis were available for 51/455 patients randomized. At baseline, week 2 and week 18, we detected ≥1 CTC/22.5ml in 5/46 (11%), 4/41 (10%), and 5/31 (16%) patients and ≥1 HER2-positive CTC/22.5ml in 2/46 (4%), 2/41 (5%), and 3/31 (10%) patients with evaluable samples, respectively. 11/51 patients (21%) had ≥1 CTC/22.5ml in at least one time point. pCR was observed in 3/11 (27.3%) versus 17/40 (42.5%) patients with detectable and no detectable CTCs, respectively (. p=0.36). No pCR was observed in the three patients with detectable HER2-positive CTCs prior to surgery. Conclusion: Numerically lower pCR rates were observed in patients with detectable CTCs, yet the study remains underpowered. A meta-analysis of CTC studies in this setting is warranted.
AB - Background: The role of circulating tumor cells (CTCs) in HER2-positive breast cancer patients receiving neoadjuvant therapy is unclear. Patients & methods: We describe the CTC detection rate, HER2 phenotyping and pathological complete response (pCR) in patients enrolled in the NeoALTTO phase III trial. Participation in the CTC sub-study was optional. CTC evaluation was performed centrally using CellSearch® at baseline, week 2 and week 18 (prior to surgery) of neoadjuvant therapy. Results: Samples for CTC analysis were available for 51/455 patients randomized. At baseline, week 2 and week 18, we detected ≥1 CTC/22.5ml in 5/46 (11%), 4/41 (10%), and 5/31 (16%) patients and ≥1 HER2-positive CTC/22.5ml in 2/46 (4%), 2/41 (5%), and 3/31 (10%) patients with evaluable samples, respectively. 11/51 patients (21%) had ≥1 CTC/22.5ml in at least one time point. pCR was observed in 3/11 (27.3%) versus 17/40 (42.5%) patients with detectable and no detectable CTCs, respectively (. p=0.36). No pCR was observed in the three patients with detectable HER2-positive CTCs prior to surgery. Conclusion: Numerically lower pCR rates were observed in patients with detectable CTCs, yet the study remains underpowered. A meta-analysis of CTC studies in this setting is warranted.
KW - Circulating tumor cells
KW - HER2-positive breast cancer
KW - Lapatinib
KW - PCR
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84887201080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887201080&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2013.08.014
DO - 10.1016/j.breast.2013.08.014
M3 - Article
C2 - 24060577
AN - SCOPUS:84887201080
SN - 0960-9776
VL - 22
SP - 1060
EP - 1065
JO - Breast
JF - Breast
IS - 6
ER -